Skip Navigation
Skip to contents




10 results

Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment

Yim EK, Bae JS, Lee SB, Lee KH, Kim CJ, Namkoong S, Um SJ, Park JS

  • Cancer Res Treat.
  • 2004 Dec;36(6):395-399.
PURPOSE: It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as carcinogens. At present, there...
Photodynamic Effects of Radachlorin(R) on Cervical Cancer Cells

Bae SM, Kim YW, Lee JM, Namkoong S, Han SJ, Kim JK, Lee CH, Chun HJ, Jin HS, Ahn WS

  • Cancer Res Treat.
  • 2004 Dec;36(6):389-394.
PURPOSE: Photodynamic therapy (PDT) is a novel treatment modality, which produces local tissue necrosis with laser light following the prior administration of a photosensitizing agent. Radachlorin(R) has recently been shown...
Expression of Matrix Metalloproteinase-9 Correlates with Poor Prognosis in Human Malignant Fibrous Histiocytoma

Yoo J, Jung JH, Kang SJ, Kang CS

  • Cancer Res Treat.
  • 2004 Dec;36(6):384-388.
PURPOSE: 92 kDa matrix metalloproteinase-9 (MMP-9) is believed to play an important role in degrading the matrix and basement membrane, contributing to the invasion and metastasis of malignant solid tumors....
An Analysis of the Risk Factors and Management of Lymphocele after Pelvic Lymphadenectomy in Patients with Gynecologic Malignancies

Kim HY, Kim JW, Kim SH, Kim YT, Kim JH

  • Cancer Res Treat.
  • 2004 Dec;36(6):377-383.
OBJECTIVES: The incidence and risk factors of lymphocele development after pelvic lymphadenectomy were evaluated and its management investigated. MATERIALS AND METHODS: This retrospective study was carried out on 264 patients...
Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients

Kim JS, Baek JY, Park SR, Choi IS, Kim SI, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK

  • Cancer Res Treat.
  • 2004 Dec;36(6):372-376.
PURPOSE: The aim of this study is to compare the antiemetic efficacy and tolerability of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed emesis. MATERIAL AND...
The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy

Shin SJ, Kim MK, Lee KH, Hyun MS, Kim SW, Song SK, Bae SH, Ryoo HM

  • Cancer Res Treat.
  • 2004 Dec;36(6):367-371.
PURPOSE: This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer. MATERIALS AND METHODS: Patients with measurable...
Responsiveness of CPT-11 in Respect to hMLH1 and hMSH2 Protein Expression in the Primary Colorectal Cancer

Park IJ, Kim HC, Yu CS, Chang HM, Lee JH, Kim JH, Kim TW, Kim JS, Kim JC

  • Cancer Res Treat.
  • 2004 Dec;36(6):360-366.
PURPOSE: The aim of this study was to evaluate the responsiveness to CPT-11 with respect to hMLH1 and hMSH2 protein expressions in primary colorectal tumors. MATERIAL AND METHODS: 91 patients...
Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal Cancer

Park JH, Kim JH, Ahn SD, Lee SW, Shin SS, Kim JC, Yu CS, Kim HC, Kang YK, Kim TW, Chang HM, Ryu MH, Choi EK

  • Cancer Res Treat.
  • 2004 Dec;36(6):354-359.
PURPOSE: Capecitabine is an attractive oral chemotherapeutic agent that has a radiosensitizing effect and tumor-selectivity. This study was performed to evaluate the efficacy and toxicity of preoperative chemoradiation therapy, when...
HIF-1alpha: a Valid Therapeutic Target for Tumor Therapy

Hong SS, Lee H, Kim KW

  • Cancer Res Treat.
  • 2004 Dec;36(6):343-353.
Hypoxia plays a major role in the induction of angiogenesis during tumor development. One mechanism by which tumor cells respond to a reduced oxygen level is via the activation of...
Preoperative Concurrent Chemoradiotherapy with Oral Fluoropyrimidine in Locally Advanced Rectal Cancer: How Good Is Good Enough?

Chung HC

  • Cancer Res Treat.
  • 2004 Dec;36(6):341-342.
No abstract available.

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: